The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
What insights can multi-omics provide into the mechanism of disease progression in WM?
Featured:
On behalf of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the Lymphoma Hub was pleased to speak with Zachary Hunter, Dana-Farber Cancer Institute, Boston, US. We asked, What insights can multi-omics provide into the mechanism of disease progression in Waldenstrom’s macroglobulinemia (WM)?
What insights can multi-omics provide into the mechanism of disease progression in WM?
Hunter begins by highlighting the importance of multi-omics in understanding the disease biology of WM, which allows better diagnosis and guides in developing targeted treatment strategies. He then goes on to discuss how focusing on DNA and RNA as “tools” is used for local regulation of genes, as well as how general epigenomics can be used to create targeted therapeutics. In addition, Hunter emphasizes the importance of using a treatment that specifically targets cancerous cells without harming healthy cells. Finally, he touches on how understanding the disease molecular mechanism is vital in multi-omics to create clusters of characteristics to better understand an individual’s disease progression and a patient’s treatment response.